GNI Group, which develops new drugs, completed its acquisition of あゆみ製薬HD in July and outlined plans to strengthen its manufacturing and marketing operations in Japan, the United States and China. An interview with CEO Ying Luo conveyed the company’s intention to pursue a second founding phase for its Japanese business.
GNI Group, which develops new drugs, completed its acquisition in July of あゆみ製薬ホールディングス, which produces Calonal. The completion of the acquisition is believed to have brought about the integration of the two companies’ businesses.
As the rationale for the acquisition, the company outlined plans to strengthen a structure for manufacturing and sales across the three markets of Japan, the United States and China, alongside expanding its presence in the Japanese market. The company is said to intend to pursue global expansion by utilizing its manufacturing capacity in Japan.
According to CEO Ying Luo, the company has spent the past 10 years exploring opportunities to expand its Japanese business. He discussed a strategy to utilize production and marketing capabilities in areas including polymer-based drugs and biologics.
Further information on the specific integration schedule and product lineup is expected to be provided through official announcements and additional interviews.